Title: SARS-CoV-2 Omicron subvariant genomic variation associations with immune evasion in

Northern California: A retrospective cohort study 4 **Authors:** Joshua R. Nugent, PhD¹; Mariah S. Wood, MPH¹; Liyan Liu, MSc¹; Teal Bullick²; Jeffrey M. 5 Schapiro, MD³; Phacharee Arunleung²; Gautham Gautham²; Shiffen Getabecha, MPH²; Christina 6 Morales, PhD²; Laura B. Amsden, MSW, MPH¹; Crystal A. Hsiao, MPH¹; Debra A. Wadford, PhD, MS²; 7 Stacia K. Wyman, PhD, MS⁴; Jacek Skarbinski, MD^{1,3,5,6} **Affiliations:** 1. Division of Research, Kaiser Permanente Northern California, Oakland, CA, 94612 2. Viral and Rickettsial Disease Laboratory, Center for Laboratory Sciences, California Department of Public Health, Richmond, California, 94804 3. The Permanente Medical Group, Kaiser Permanente Northern California, Oakland, CA, 94612 4. Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, 94720 5. Department of Infectious Diseases, Oakland Medical Center, Kaiser Permanente Northern California, Oakland, CA, 94611 6. Physician Researcher Program, Kaiser Permanente Northern California, Oakland, CA, 94612 **Running title:** Omicron genomic variation and immune evasion **Word count:** Abstract (249); Manuscript text (2,859) **Corresponding author:** Joshua R. Nugent Kaiser Permanente Division of Research 4480 Hacienda Drive, Building B Pleasanton, CA 94588 Email: joshua.r.nugent@kp.org Mobile: 628-282-1934 **Author Contributions:** • Joshua R. Nugent; Mariah S. Wood; Liyan Liu; Jeffrey M. Schapiro; Laura B. Amsden; Crystal A. Hsiao; Stacia K. Wyman; Jacek Skarbinski contributed to conceptual ideas and methodology; • Joshua R. Nugent; Mariah S. Wood; Liyan Liu; Teal Bullick; Stacia K. Wyman; Jacek Skarbinski contributed to formal analysis; • Joshua R. Nugent; Liyan Liu; Stacia K. Wyman; Jacek Skarbinski contributed to writing and original draft preparation; • Joshua R. Nugent; Mariah S. Wood; Liyan Liu; Teal Bullick; Jeffrey M. Schapiro; Phacharee Arunleung; Gautham Gautham; Christina Morales; Laura B. Amsden; Crystal A. Hsiao; Debra A. Wadford; Stacia K. Wyman; Jacek Skarbinski contributed to writing, reviewing, and editing the manuscript; • Jacek Skarbinski; Phacharee Arunleung; Christina Morales; Debra A. Wadford supervised the work. **Declaration of interests:** All authors: No conflicts of interest identified. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant 46 to the content of the manuscript have been disclosed.

Abstract

- **Background:** The possibility of association between SARS-CoV-2 genomic variation and immune evasion
- is not known among persons with Omicron variant SARS-CoV-2 infection.
- **Methods:** In a retrospective cohort, using Poisson regression adjusting for sociodemographic variables
- and month of infection, we examined associations between individual non-lineage defining mutations
- and SARS-CoV-2 immunity status, defined as a) no prior recorded infection, b) not vaccinated but with at
- least one prior recorded infection, c) complete primary series vaccination, and/or d) primary series
- vaccination and ≥ 1 booster. We identified all non-synonymous single nucleotide polymorphisms (SNPs),
- insertions and deletions in SARS-CoV-2 genomes with ≥5% allelic frequency and population frequency of
- ≥5% and ≤95%. We also examined correlations between the presence of SNPs with each other, with
- subvariants, and over time.
- **Results:** Seventy-nine mutations met inclusion criteria. Among 15,566 persons infected with Omicron
- SARS-CoV-2, 1,825 (12%) were unvaccinated with no prior recorded infection, 360 (2%) were
- unvaccinated with a recorded prior infection, 13,381 (86%) had a complete primary series vaccination,
- and 9,172 (58%) had at least one booster. After examining correlation between SNPs, 79 individual non-
- lineage defining mutations were organized into 38 groups. After correction for multiple testing, no
- individual SNPs or SNP groups were significantly associated with immunity status levels.
- **Conclusions:** Genomic variation identified within SARS-CoV-2 Omicron specimens was not significantly
- associated with immunity status, suggesting that contribution of non-lineage defining SNPs to immune
- evasion is minimal. Larger-scale surveillance of SARS-CoV-2 genomes linked with clinical data can help
- provide information to inform future vaccine development.

Key words: SARS-CoV-2; genomic variation; immune evasion

Background

4.5 million members in Northern and Central California and provides comprehensive preventive and

 met the following criteria: 1) KPNC membership for at least one year prior to SARS-CoV-2 diagnosis; 2) aged ≥5 years and <90 years; 3) no prior receipt of COVID-19 vaccine or the completion of a primary COVID-19 vaccine series of two doses of BNT162b2 [Pfizer/BioNTech] or m-RNA-1973 [Moderna/National Institutes of Health] or one dose of Ad.26.COV2.s [Janssen] more than 14 days prior to index date; 4) incident infection defined as the first NAAT-confirmed SARS-CoV-2 infection during the study period. The index date was defined as the date of NAAT-confirmation of SARS-CoV-2 infection. *SARS-CoV-2 whole genome sequencing and processing* KPNC is a partner in COVIDNet with CDPH and submits a majority of NAAT-confirmed SARS-CoV- 2 specimens to COVIDNet for genomic surveillance; a subset of specimens undergo whole genome sequencing at CDPH or affiliated laboratories based on CDPH priorities, including prioritizing hospitalized 131 cases and a convenience sample of the first specimens received per week (number varies by burden).⁶ COVIDNet consists of a set of (primarily University of California-affiliated) laboratories tapped to assist CDPH because they had surplus sequencing capacity. Illumina sequencing was used by most of the sites, with about 10% of genomes being sequenced by Oxford Nanopore. For this study, we only included Illumina-sequenced genomes because the error rate of Nanopore is too high to accurately identify low- frequency mutations. Varying sets of primers were used by different institutions, but the most common for the Omicron genomes were the ARTICv3 and ARTICv4 primers. The University of California, San Francisco lab used their own custom set of primers with more primers and shorter amplicons. After sequencing, the CDPH Viral and Rickettsial Disease Laboratory links lineage information with patient identifiers and shares the results with KPNC. The raw sequence files are shared with the University of California, Berkeley (UCB); KPNC and UCB collaborate further to link demographic, clinical, and

epidemiologic data from KPNC with subsequent sequence analysis data from UCB.

 The raw sequencing data were processed through a SARS-CoV-2 analysis pipeline that was modified for this work as follows. Adapter removal and trimming were performed using bbduk (http://sourceforge.net/projects/bbmap/). The reads were then aligned to the Wuhan reference 146 genome (GISAID ID: EPI_ISL_402125, GenBank accession number MN908947) using minimap2⁷ followed 147 by primer trimming using iVar.⁸ Samtools was used to create a pileup file from which a consensus sequence was generated. This consensus genome was created with iVar using a minimum depth of 10 reads and majority rule for base calling. We next used iVar to call variants from the pileup file where we set the sensitivity threshold for calling a mutation to 2%. This process calls mutations for any loci where at least 2% of the reads are non-reference. Using this very low threshold allowed us to capture even very low frequency mutations in the sequencing data. This threshold resulted in many spurious mutations from sequencing and alignment errors and therefore we later set a threshold of 5% when processing mutations. This original list of variants was then annotated with the gene and amino acid change (if there was one) or insertion or deletion. After calling with iVar using a low-frequency threshold, mutations were compiled into a master frequency matrix listing all mutations that appeared in any genome in rows, and all the genomes that 158 each mutation appeared in columns [\(https://github.com/staciawyman/SC2_GenVar\)](https://github.com/staciawyman/SC2_GenVar). The cell values were frequency of the alternate reads at the location. A mutation had to have an allele frequency of at least 5% to be included to rule out sequencing errors. This matrix was partitioned into variant-specific parts to facilitate analysis. We constructed an Omicron matrix including all individuals that had the 162 Omicron lineage⁹ between January 1, 2022 and October 31, 2022 including non-synonymous SNPs, insertions and deletions (indels). Pipeline code is available at https://github.com/staciawyman/SC2_GenVar.

Outcome measure

 Adjusted relative prevalence, shown as an adjusted rate ratio (aRR), and 95% confidence intervals (CIs) for the estimates for our exposure and adjustment variables were obtained from modified Poisson regression models with robust standard errors using PROC GENMOD with a log link function in SAS (Version 9.4, Cary, North Carolina); statistical significance was defined as a p-value <0.05. All p- values were adjusted for multiple comparisons to control the false discovery rate at 5%, using the 187 Benjamini-Hochberg procedure.¹⁰ To adjust for confounding, all models included age category, sex, 188 race/ethnicity, Charlson comorbidity index score¹¹, and index month. Adjusting for these demographic and clinical factors accounted for differential vaccination status of these subgroups, increasing

 vaccination rates over time, and the inherent uncertainty as to where in a population a new mutation might arise. *Data Availability* De-identified data that underlie the results reported in this article will be made available upon reasonable request. *Role of funding source* The funders had no role in study design, data collection, data analysis, interpretation, or writing of the report. **Results** From January 1, 2022 to October 31, 2022, 312,249 SARS-CoV-2-positive specimens were submitted for sequencing, 18,603 (6.0%) underwent sequencing (Supplemental Figure 1), and 18,476 (5.9%) had reported lineages consistent with the Omicron variant. After applying selection criteria, 15,556 persons with SARS-CoV-2 Omicron variant infection were included in the analysis: 9,172 (58%) vaccinated with a booster; 4,209 (26%) vaccinated with a complete primary series [two doses of Pfizer or Moderna vaccine]; and 2,185 (14%) with no vaccination (Supplemental Figure 1). The prevalence of Omicron subvariants in our specimens, aggregated to the week level, showed increasing diversity over time (Figure 1). After applying selection criteria to the sequences, we identified 78 non-lineage defining mutations (all non-synonymous SNPs) in 1,456 SARS-CoV-2 SNPs included in this analysis, shown in Supplemental Figure 2. Identified mutations were in the spike gene (n=44), nucleocapsid gene (n=8) open reading frame 1a (ORF1a) (n=19), ORF1b (n=4), ORF3a (n=1), ORF6c (n=1), ORF10 (n=1). The

 population frequency within our genomes of individual identified mutations ranged from 5.0% to 95.0% and 46 out of 79 (58.2%) mutations were present in <50% of the overall population. Although we called low-frequency mutations with our pipeline, none of them met the criteria for inclusion in our analysis. Of the 78 identified SNPs that met our inclusion criteria, many co-occurred on the same specimens. Supplemental Figure 2 shows the pairwise correlations of SNP presence in our dataset. Given the strong pairwise correlations observed, we formed groups of SNPs that had a pairwise Pearson correlation > .7, reducing the dimension to 33 SNPs/SNP groups, also shown in Supplemental Figure 2. These mutation groups are largely monophyletic and segregate together across the phylogeny of Omicron genomes (Supplemental Figure 3). The demographics of persons with SARS-CoV-2 infection included in this analysis, stratified by vaccination and prior infection status, are shown in Table 1, and the number of total reported infections and those sequenced over time is shown in Supplemental Figure 4. Significant differences were found between groups, thus supporting their inclusion in our covariate adjustment set. Figure 2 details some 227 of the relationships between SNP groups, time, and subvariant among the specimens in our data set. While certain mutations/groups appear essentially only in a single subvariant (for example, 99.1% of S:H69L mutations appear in specimens classified as BA.1 in Figure 2c), the majority of mutations/groups appear in many subvariants, suggesting that they are not simply proxy measures of subvariant. Further, the presence of mutations/groups do not follow clear temporal patterns (Figure 2b). While some mutations such as Group 12 arise, become plentiful, then wane, others disappear and re-appear over time without a clear pattern (for example, S:D1259H). Smoothed over time, grouped SNP prevalence by month is shown in Supplemental Figure 5. Using modified Poisson regression models with robust standard errors, we found several of our 33 SNP groupings (Table 2) and/or 78 individual mutations (Supplemental Table 1) that were

significantly associated with immunity status; however, after correcting p-values to adjust for multiple

 previously implicated with immune evasion were excluded based on population frequency. We encourage future research to examine the entire viral genome for potential immune evasion or increased replication or infectivity.

 Our results showed that there appear to be some mutations that are tightly grouped with certain subvariants, while a number of other mutations appear across multiple subvariants. While we 267 did not find evidence for immune evasion among our identified mutations/groups after correction for multiple testing, it is possible that we are underpowered to detect small effects over a short time 269 period.¹² Many of the SNPs with the highest adjusted risk ratios appeared in a small number of specimens (Supplemental Table 1). While one would expect more variability from the smallest table cells 271 if we were simply observing statistical noise, it is also possible that a larger sample could confirm these stronger adjusted risk ratios.

 Our analysis has several limitations. First, not all possible demographic and clinical variables were included in our models, and if those variables are associated with immunity status and SNP presence, unmeasured confounding could bias our analysis. Second, there is a risk of misclassification of immunity status; though the KPNC surveillance system for vaccination is quite robust, prior infections (say, diagnosed by a home test) may have gone unreported. Third, we focused on a set of specimens from Northern and Central California, limiting the generalizability of our findings to this context. Finally, there may be hidden bias as to which specimens were successfully sequenced based on the nucleic acid viral load in the specimen (e.g., specimens with lower viral loads might not be successfully sequenced 281 and thus would have been excluded from this analysis). Fourth, although our surveillance system has a very robust system for assessing individual-level vaccination status, there is a small risk of misclassification of persons as having incorrect immunity status. As part of the global effort to conduct near real-time genomic surveillance for SARS-CoV-2, there

has been tremendous progress in developing national genomic surveillance systems with nearly real-

available upon reasonable request.

- **Disclaimer:** The content is solely the responsibility of the authors and does not represent the official
- views or opinions of the National Institutes of Health, Kaiser Permanente, California Department of
- Public Health or the California Health and Human Services Agency.

- ***Additional Disclaimer:** Use of trade names and commercial sources is for identification only and does
- not imply endorsement by the California Department of Public Health or the California Health and
- Human Services Agency.

References

- 1. Lou F, Li M, Pang Z, et al. Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and
- Immune Escape. *Front Immunol*. 2021;12. Accessed November 13, 2023.
- https://www.frontiersin.org/articles/10.3389/fimmu.2021.744242
- 2. Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune
- escape. *Nat Rev Microbiol*. 2021;19(7):409-424. doi:10.1038/s41579-021-00573-0
- 3. Davis AC, Voelkel JL, Remmers CL, Adams JL, McGlynn EA. Comparing Kaiser Permanente Members
- to the General Population: Implications for Generalizability of Research. *Perm J*. 2023;27(2):87-98.
- doi:10.7812/TPP/22.172
- 4. Ross TR, Ng D, Brown JS, et al. The HMO Research Network Virtual Data Warehouse: A Public Data
- Model to Support Collaboration. *EGEMS Wash DC*. 2014;2(1):1049. doi:10.13063/2327-9214.1049
- 5. Weeks J, Pardee R. Learning to Share Health Care Data: A Brief Timeline of Influential Common Data
- Models and Distributed Health Data Networks in U.S. Health Care Research. *EGEMS Wash DC*.
- 2019;7(1):4. doi:10.5334/egems.279
- 6. Wadford DA, Baumrind N, Baylis EF, et al. Implementation of California COVIDNet a multi-sector
- collaboration for statewide SARS-CoV-2 genomic surveillance. *Front Public Health*. 2023;11.
- Accessed November 26, 2023. https://www.frontiersin.org/articles/10.3389/fpubh.2023.1249614
- 7. Li H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinforma Oxf Engl*.
- 2018;34(18):3094-3100. doi:10.1093/bioinformatics/bty191
- 8. Grubaugh ND, Gangavarapu K, Quick J, et al. An amplicon-based sequencing framework for
- accurately measuring intrahost virus diversity using PrimalSeq and iVar. *Genome Biol*. 2019;20(1):8.
- doi:10.1186/s13059-018-1618-7
- 9. O'Toole Á, Scher E, Underwood A, et al. Assignment of epidemiological lineages in an emerging
- pandemic using the pangolin tool. *Virus Evol*. 2021;7(2):veab064. doi:10.1093/ve/veab064

- 10. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to
- Multiple Testing. *J R Stat Soc Ser B Methodol*. 1995;57(1):289-300. doi:10.1111/j.2517-
- 6161.1995.tb02031.x
- 11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity
- in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373-383.
- doi:10.1016/0021-9681(87)90171-8
- 12. Volz E. Fitness, growth and transmissibility of SARS-CoV-2 genetic variants. *Nat Rev Genet*.
- 2023;24(10):724-734. doi:10.1038/s41576-023-00610-z
- 13. Chen Z, Azman AS, Chen X, et al. Global landscape of SARS-CoV-2 genomic surveillance and data
- sharing. *Nat Genet*. 2022;54(4):499-507. doi:10.1038/s41588-022-01033-y
- 14. World Health Organization. *Guidance for Surveillance of SARS-CoV-2 Variants: Interim Guidance, 9*
- *August 2021*. World Health Organization; 2021. https://apps.who.int/iris/handle/10665/343775
- 15. Lambrou AS. Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2)
- and Omicron (B.1.1.529) Variants United States, June 2021–January 2022. *MMWR Morb Mortal*
- *Wkly Rep*. 2022;71. doi:10.15585/mmwr.mm7106a4
- 16. Robishaw JD, Alter SM, Solano JJ, et al. Genomic surveillance to combat COVID-19: challenges and
- opportunities. *Lancet Microbe*. 2021;2(9):e481-e484. doi:10.1016/S2666-5247(21)00121-X
- 17. Tonkin-Hill G, Martincorena I, Amato R, et al. Patterns of within-host genetic diversity in SARS-CoV-
- 2. Neher RA, Sawyer SL, Neher RA, Lauring AS, eds. *eLife*. 2021;10:e66857. doi:10.7554/eLife.66857
- 18. Gao R, Zu W, Liu Y, et al. Quasispecies of SARS-CoV-2 revealed by single nucleotide polymorphisms
- (SNPs) analysis. *Virulence*. 2021;12(1):1209-1226. doi:10.1080/21505594.2021.1911477
- 19. Nicholls SM, Poplawski R, Bull MJ, et al. CLIMB-COVID: continuous integration supporting
- decentralised sequencing for SARS-CoV-2 genomic surveillance. *Genome Biol*. 2021;22(1):196.
- doi:10.1186/s13059-021-02395-y
-

Figure 1. SARS-CoV-2-positive specimens tested by Kaiser Permanente Northern California, proportion by subvariant, by week from January 1, 2022 to October 31, 2022

Calendar time by week, January 2022 to October 2022

Figure 2: SNP/group prevalence by subvariant and week in 2022

- (A) Proportion of specimens in each sublineage by week
- (B) Proportion of specimens with a given SNP/group by week
- (C) Proportion of subvariant by SNP/group (rows sum to 100%)

1Wilcoxon rank sum test; Pearson's Chi-squared test

²Immune compromising conditions: HIV, organ transplant, cancer, rheumatologic/inflammatory conditions, and other immune deficiencies.

¹ Mutations with Pearson pairwise correlation >0.70 combined into groups for analysis:

- group 4: M:D3G, ORF1a:I3758V, ORF1a:K856R, S:A67V, S:G496S, S:N211I, S:N856K, S:R346K,
- S:S371P, S:T22204+GAGCCAGAA, S:T547K, S:T95I
- group 6: N:S413R, ORF1a:F3677L, ORF1a:G1307S, ORF1a:L3027F, ORF1a:S135R, ORF1a:T3090I, ORF1a:T842I, ORF1b:R1315C, ORF1b:T2163I, ORF3a:T223I, S:D405N, S:G142D, S:L24S, S:T19I, S:T376A, S:V213G group 7: S:L452Q, S:S704L
- group 11: S:E484A, S:N501Y, S:Q498R, S:S477N, S:T478K, S:Y505H
- group 12: ORF1a:L3201F, ORF6:D61L
- group 19: S:S371F, S:S373P, S:S375F
- group 20: S:K417N, S:N440K
- group 25: M:D3N, S:F486V, S:L452R
- group 26: ORF1a:A2710T, ORF1a:L3674F, S:G21986-GTGTTTATT, S:G22193-ATT, S:G446S, S:L981F
- group 45: S:A27S, S:C1254*
- group 64: N:P151S, ORF1a:F143L

² Adjusted risk ratios derived from Poisson regression models to assess the association of immunity status with each mutation group adjusting for age, sex, race/ethnicity, Charlson comorbidity index score, and month of SARS-CoV-2 infection.

Supplemental Figure 1. Cohort flowchart

Supplemental Figure 2: Pearson correlations of SNP presence in specimens, before and after clustering.

Supplemental Figure 3. Phylogenies of 15,045 Omicron genomes colored by group. Mutations in group 52 (top) represent a clade defined by the BA.2.12.1 subvariant (in blue). Mutations in group 4 (bottom) fall into a subclade of BA.4 (in yellow).

Supplemental Figure 4. Persons with SARS-CoV-2 infection tested by Kaiser Permanente Northern California stratified by subvariant by week from January 1, 2022 to October 31, 2022

Supplemental Figure 5. Proportion of specimens with a given SNP or group, by month of 2022

Supplemental Figure 6. Phylogeny of 15,045 Omicron genomes sampled between 1/1/2022 and 9/25/22. Branch lengths represent divergence from Wuhan reference genome and nodes are colored by vaccination status. Vaccinated category includes primary series and primary plus booster.

Supplemental Table 1: Association between SNP presence and vaccine status (pooling over complete and boosted) among persons included in this analysis with SARS-CoV-2 infection with Omicron variant in Northern California, January 1, 2022 - October 31, 2022 (N=15,566).

 1 Poisson regression models to assess the association of breakthrough infection with each individual mutation adjusting for age, sex, race/ethnicity, Charlson comorbidity index score, and month of SARS-CoV-2 infection. None of the p-values were significant after adjustment for multiple testing.

Supplemental Table 2: Association between SNP presence and vaccine status (separating out complete and boosted) among persons included in this analysis with SARS-CoV-2 infection with Omicron variant in Northern California, January 1, 2022 – October 31, 2022 (N=15,566)

 1 Poisson regression models to assess the association of breakthrough infection with each individual mutation adjusting for age, sex, race/ethnicity, Charlson comorbidity index score, and month of SARS-CoV-2 infection. None of the p-values were significant after adjustment for multiple testing.

Supplemental Table 3: Association between mutation groups¹ and vaccine status (separating complete and boosted) **among persons included in this analysis with SARS-CoV-2 infection with Omicron variant in Northern California, January 2022-October 2022 (N=15,566) ²**

¹ Mutations with Pearson pairwise correlation >0.70 combined into groups for analysis:

- group 4: M:D3G, ORF1a:I3758V, ORF1a:K856R, S:A67V, S:G496S, S:N211I, S:N856K, S:R346K,
- S:S371P, S:T22204+GAGCCAGAA, S:T547K, S:T95I
- group 6: N:S413R, ORF1a:F3677L, ORF1a:G1307S, ORF1a:L3027F, ORF1a:S135R, ORF1a:T3090I, ORF1a:T842I, ORF1b:R1315C, ORF1b:T2163I, ORF3a:T223I, S:D405N, S:G142D, S:L24S, S:T19I, S:T376A, S:V213G group 7: S:L452Q, S:S704L
- group 11: S:E484A, S:N501Y, S:Q498R, S:S477N, S:T478K, S:Y505H
- group 12: ORF1a:L3201F, ORF6:D61L
- group 19: S:S371F, S:S373P, S:S375F
- group 20: S:K417N, S:N440K
- group 25: M:D3N, S:F486V, S:L452R
- group 26: ORF1a:A2710T, ORF1a:L3674F, S:G21986-GTGTTTATT, S:G22193-ATT, S:G446S, S:L981F
- group 45: S:A27S, S:C1254*
- group 64: N:P151S, ORF1a:F143L

² Adjusted risk ratios derived from Poisson regression models to assess the association of immunity status with each mutation group adjusting for age, sex, race/ethnicity, Charlson comorbidity index score, and month of SARS-CoV-2 infection.